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Child development is a unique and continuous process that is impacted by genetics and
environmental factors. Gut microbiome changes with development and depends on the
stage of gut maturation, nutrition, and overall health. In spite of emerging data and
active study in adults, the gut-renal axis in pediatrics has not been well considered and
investigated. This review will focus on the current knowledge of gut microbiota impacts
on kidney disease with extrapolation to the pediatric population.
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INTRODUCTION
Summary of Microbial Activities in Human Metabolism
Knowledge of the microbial communities living in human body is increasing at a fast pace. The
Human Microbiome Project demonstrated that humans might be considered superorganisms,
composed of human and microbial components, interacting in a symbiotic manner (Turnbaugh
et al., 2007). Microbial population has coexisted with humans in a state of mutually beneficial
cohabitation and plays an important role in health and disease (Cani and Delzenne, 2009). Inter-
organismal crosstalk interruption leads to profound and diverse cellular and metabolic changes
observed in gut dysbiosis (Hooper and Gordon, 2001). Gordon et al. showed that the composition
of the gut microbiome affects metabolism and energy homeostasis (Ley et al., 2007; Turnbaugh
et al., 2007). The gut microbiome is a biotic factor regulating body weight, and thus linked to obesity
and other metabolic disorders (Ley et al., 2006) and (Cani and Delzenne, 2009). Maintaining
the symbiotic equilibrium between gut microbiome and host in different pathological conditions
remains a challenge for the physicians. The understanding of their interaction, manipulation of
the structure and functions of human microbiota may allow effective prevention and treatment of
many diseases.
Small Intestinal Bacterial Overgrowth may Triggers CKD/ESRD
Dysbiosis can be promoted by any inflammatory reaction, making it difficult to discern cause and
consequence of the disease (Sansonetti, 2008; Anders et al., 2013). The gut microbiome could be a
trigger for the deregulated immune system in kidney disease (Anders et al., 2013).
Anders et al. (2013) pointed out that the metabolic alterations of uremia favor gut pathogen
overgrowth. But this fact has been largely neglected as a trigger for chronic kidney disease
(CKD)/end-stage renal disease (ESRD)-related immune derangements (Martin et al., 2009). The
concept was that pathobiont overgrowth induces inflammation and loss of barrier function
that, results in increased translocation of bacterial components such as LPS and other immune
stimulating proteins. This process activates innate immunity characterized by production of pro-
inflammatory cytokines and modulates a number of clinically relevant processes in CKD such as
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the progression of CKD, accelerated atherogenesis, and protein
wasting (Anders et al., 2013). Data from a previous studies
indicated that toxic products generated by a dysbiotic gut
microbiome may contribute to progression of CKD and CKD-
related complications (Stecher et al., 2007; Wu et al., 2011;
Ramezani and Raj, 2014). As a result, a hypothesis was developed
that probiotics and prebiotics reduce progression of CKD and
associated uremia by optimizing the gut microbiome (Lin et al.,
2011).
With a comprehensive understanding of the structure, density,
and function of the gut microbiota, new therapeutic targets
could be identified and utilized for a healthier gut. A healthy
gut could help improve overall well-being (Vitetta and Gobe,
2013) including health improvement for children with acute and
chronic renal conditions.
During development, human microbiome stimulates and
synchronizes with the host innate immune functions by the
classical complement pathway, the alternate pathway, and the
mannose-binding lectin pathway. Kidney disease such as atypical
hemolytic uremic syndrome (aHUS) and membranoproliferative
glomerulonephritis are closely linked to abnormalities in
complement activation due to host genetic anomalies (Sugimoto
et al., 2012). Animal experiments have also established that the
microbiota modulate the expression of host genes (Bäckhed
et al., 2004). Moreover gnotobiotic mouse models revealed that
different members of the microbiota induce different types of
immune responses (Ivanov et al., 2009). A mixture of Clostridium
sp. demonstrated induction of FoxP3+ regulatory T cells and
the segmented filamentous bacteria promoted T helper type 17
cell differentiation (Soulage et al., 2013). Animal models have
advanced our understanding of the role of microflora in human
disease. However, animal conditions can only mimic the features
of human disorders (Nagpal et al., 2014). The gut microbiota
produces uremic toxins such as advanced glycation end-products,
phenols [e.g., p-cresyl sulfate (PCS)], and indoles [e.g., indoxyl
sulfate (IS); Bone et al., 1976; Tlaskalová-Hogenová et al., 2011;
Hegab et al., 2012]. Animal studies have shown that the biological
effect of these molecules include induction of pro-inflammatory
responses, leukocyte stimulation, and endothelial dysfunction.
These conditions play a substantial role in the development and
progression of multiple causes of acute kidney injury (AKI) and
CKD (Charney et al., 1993; Motojima et al., 2003; Schepers et al.,
2007; Macfarlane and Macfarlane, 2012). IS and PCS are renal
and cardiovascular toxins, produced solely by the gut microbiota,
which have pro-inflammatory and pro-oxidative properties (Dou
et al., 2004). Animal studies have shown that uremic toxins may
promote the progression of chronic renal failure by damaging
tubular cells (Rossi et al., 2014).
Many reports showed that the composition of gut microbiota
is different in CKD patients. Vaziri et al. (2012), using a rat model,
showed CKD alters the composition of intestinal microbial
flora (Claus et al., 2008). The study revealed substantially less
species richness as measured by the number of operational
taxonomic units (OTUs) in the nephrectomized rats compared
with the controls (Vaziri et al., 2012). The mechanism of
bacterial gut alteration was thought to be the result of multiple
factors including, but not limited to, metabolic acidosis, volume
overload, intestinal wall congestion retention, uremia, frequent
use of antibiotics, oral iron, and intestinal ischemia (Kang,
1993; Maslowski and Mackay, 2011; Vaziri et al., 2012).
Animal experiments also showed that persistent inflammation
contributed to the high rates of CKD development (Vaziri et al.,
1985; Stenvinkel et al., 1999).
Some thought that a healthy high fiber diet might promote
significant colonization with Shiga toxins-producing Escherichia
coli, which can lead to hemolytic-uremic syndrome (HUS; Ivanov
et al., 2009). Interesting work by Eaton et al. (2011), showed
that the probiotic Lactobacillus reuteri (ATCC PTA 6475) was
effective in suppressing disease symptoms of HUS. Their data
indicated that L. reuteri partially protected mice from disease
manifestations (Eaton et al., 2011). The progression of CKD was
hindered by ‘enteric dialysis’ by administering non-pathogenic
soil-borne alkalophilic urease-positive bacterium Sporosarcina
pasteurii (Sp) in 5/6 nephrectomized rats. That pilot study
demonstrated that rats fed with 109 cfu/day of live Sp had reduced
blood urea-nitrogen levels and showed significantly prolonged
lifespans (Mandal et al., 2013). Furthermore, in germ-free mice
that are lacking in immune related to inflammation, the gut
microbiome was found to influence kidney homeostasis with
elevated levels of key cell volume regulators (betaine, choline, and
myo-inositol) in kidneys (Ranganathan et al., 2006).
Obesity and metabolic disorders link tightly to kidney
disease. Studies in mice demonstrated that an interrelationship
exists between energy balance, diet, and the composition of
the gut microbial community. This interrelationship might
have significant clinical implications including obesity related
complications (Bäckhed et al., 2004, 2007; Ley et al., 2005;
Turnbaugh et al., 2006; Clavel and Haller, 2007). In a murine
model, gut microbiome product PCS interfered with intracellular
insulin signaling pathways and triggered insulin resistance. The
treatment of CKD mice with a prebiotic reduced the intestinal
production and blood levels of PCS and prevented insulin
resistance and lipid abnormalities (Turnbaugh et al., 2008).
To improve animal models to study the human microbiome,
a gnotobiotic piglet model was developed (Wang and Donovan,
2015) furthermore human microbiota-associated (HMA) piglets
have been established using inocula from infants, children,
and adults. The gut microbiota of recipient HMA piglets
was more similar to that of the human donor than that
of conventionally reared piglets harboring a pig microbiota.
Moreover, Bifidobacterium and Bacteroides, two predominant
bacterial groups of the infant gut, had been successfully
established in the HMA piglets.
WHAT DID WE LEARN ABOUT GUT
MICROBIOME AND RENAL FUNCTION
FROM ANIMAL STUDIES?
Understanding impact of gut microbiome and pathobiome
in renal pathology might bring a critical new knowledge in
understanding genesis and treatment of kidney disease. The
metagenomics approach has the potential to uncover entirely
novel genes, gene families, and their encoded proteins, which
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might be of biotechnological and pharmaceutical relevance
(Belizario and Napolitano, 2015). Therefore, animal models
strongly proved impact on gut microbiome and renal function, in
addition suitable animal models were created to pursue relevant
study in pediatric population.
GUT MICROBIOME AND RENAL AXIS IN
ADULT POPULATION
An adult human’s microbiome is diverse and dependent upon
health status, diet, and geographic location. The gut harbors
a complex mixture of tens of trillions of microbes, comprised
of more than 1,000 diverse species of identified bacteria with
over three million genes. In healthy individuals, the phyla
Bacteroidetes and Firmicutes contribute >90% of all species,
including abundant bacterial genera such as Bacteroides sp.,
Alistipes sp., Prevotella sp., Porphyromonas sp., Clostridium sp.,
Dorea sp., Faecalibacterium sp., Eubacterium sp., Ruminococcus
sp., and Lactobacillus sp. Other less abundant phyla include the
Actinobacteria (that is, Bifidobacterium sp. and Collinsella sp.),
Proteobacteria (that is, Enterobacteriaceae, Sutterella sp., and
Helicobacter sp.), Verrucomicrobia (that is, Akkermansia sp.),
and some others (Qin et al., 2010).
The microbiota colonizing the gut control the normal
development and function of the mucosal barriers, support
food digestion, and defend the individual from circulation of
pathogenic micro-organisms. On the other hand, the break down
of proteins and peptides by colonic microorganisms yields a great
diversity of end-products, many of which have toxic properties
(Mafra et al., 2013).
Adult uremic patients show greatly increased counts of
both aerobic and anaerobic organisms in the duodenum and
jejunum, portions of the intestines not normally colonized
heavily by bacteria in healthy persons (Ramezani and Raj, 2014).
With diminished kidney clearance, quantitative, and qualitative
alterations in gut microbiota were noted in adult patients with
CKD and ESRD (Hida et al., 1996; Simenhoff et al., 1996;
Vaziri et al., 2013). Vaziri et al. (2013) showed significant
differences in the abundance of 190 microbial OTUs between
the patients with ESRD and the normal control individuals. In
addition, hemodialysis patients had significantly lower numbers
of Bifidobacteria and higher Clostridium perfringens numbers
(Rossi et al., 2014).
Intestinal microbial flora in patients with CKD characterized
by decreases in both Lactobacillaceae and Prevotellaceae families
have been reported (Mafra et al., 2014). As a result, uremic toxins
produce bacteria families’ over growth that impacts immune
response and inflammatory reactions. Study in 149 CKD patients
with a mean estimated Glomerular Filtration Rate (eGFR) of
40 ± 9 mL/min/1.73 m2 showed that serum free and total IS
were independently associated with increased levels of serum IL-
6, TNF-α, and IFN-γ, whereas serum free and total PCS were
independently associated with increased levels of serum IL-6
and pulse wave velocity (Rossi et al., 2014). This study for the
first time proved a strong connection between produced and
retained uremic toxins and demonstrated strong predictors of
cardiovascular mortality in CKD patients. The idea was further
supported by a publication of Mafra et al. (2014). They also
provided a concise description of the potential role of the CKD-
associated changes in the gut microbiome and its potential role
in the pathogenesis of inflammation and uremic toxicity (Mafra
et al., 2014). PCS also contributed to the development of insulin
resistance in patients with CKD (Soulage et al., 2013).
Lipopolysaccharide (LPS)-induced monocyte/macrophage
activation could explain systemic inflammation and might be
relevant to CKD/ESRD patients’ conditions (Stearns-Kurosawa
et al., 2011). Cani et al. (2007) demonstrated in mouse model
that the metabolic endotoxemia dysregulates the inflammatory
character and activates body weight gain and diabetes. They also
observed that lowering plasma LPS concentration could be an
effective approach to regulate metabolic diseases such as diabetes
(Cani et al., 2007).
We recently reported significant increases in inflammatory
markers and markers of endothelial dysfunction in patients with
diabetes, CKD, and ESRD on peritoneal dialysis, as well as
correlations with levels of LPS and zonulin (a gut permeability
marker; Chennasamudram et al., 2013; Nakhla et al., 2014; Singh
et al., 2014). Human intestine also acts as an active player by
presenting more precursors for fermentation due to disturbances
in assimilation caused by uremia, followed by alterations in
further processing related to changes in the composition of the
fermenting flora (Schepers et al., 2010). Deficiency in vitamin K
and calcidiol is a common feature among patients with CKD and
ESRD and is likely attributed to gut dysbiosis (LaClair et al., 2005;
Pilkey et al., 2007).
The colonic microbiome is an active site of methanol
production, which might appear in the exhaled breath of
subjects. The study of methanol breath content in ESRD
on hemodialysis showed that methanol production could be
substantially manipulated by the diet, which changed gut
populations per se (Lee et al., 2012).
Strong connection between gut pathobionts and CKD and
ESRD in adult population is nowadays undoubtful fact. The next
important questions to be answered in nephrology: how gut
microbiome diversity impacted by primary renal disease and how
it changes with progression of chronic renal impairment.
PEDIATRIC GUT MICROBIOME
The gastrointestinal tract (GIT) in neonates was thought to be
almost sterile at birth and then rapidly colonized by bacteria
shortly after delivery until an adult type composition was
acquired around the first to the third year of life (Rotimi and
Duerden, 1981; Valle et al., 2007; DiGiulio et al., 2008; O’Toole
and Claesson, 2010). This view has recently been challenged by
reports of detection of diverse microbes in placenta, umbilical
cord, amniotic fluid, and meconium (Jiménez et al., 2005,
2008; Dominguez-Bello et al., 2010; Vallés et al., 2012; Gosalbes
et al., 2013; Moles et al., 2013; Song et al., 2013; Aagaard
et al., 2014). It is now well established that during the first
3 years of life, children experience significant developmental
changes that influence their health status as well as their
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immune system. Using sequential fecal analysis in a large cohort,
human microbiome studies across North America, Africa, South
America, and Europe, have made it apparent that gut microbiome
is highly unstable during the first 3 years of life (De Filippo et al.,
2010; Koenig et al., 2011; Yatsunenko et al., 2012). The pattern
of GIT microbiome development during child development is
summarized in Figure 1.
GUT MICROBIOME IN CHILDREN WITH
KIDNEY DISEASE
The relationship between alterations in the gut microbiome and
its possible involvement in the development of renal disease later
in life is an important venue to be investigated. Consideration of
GIT barrier structure and it changes in pathological conditions
is necessary to understand relationships in the gut-renal axis
in pediatrics. The maintenance of a healthy intestinal barrier
is extremely important in children. There are multiple layers,
which makeup the barrier between gut lumen and the rest of the
body. The physical barrier is composed of gut microbiota, mucus,
epithelial cells, and the innate and adaptive immune cells forming
the gut-associated lymphoid tissue. The internal mucosal layer is
dense and does not allow bacteria to penetrate, while the external
mucus layer is the habitat of the gut microbiota. Each of those
layers is compromised in a uremic condition (Figure 2).
As mentioned above, in a healthy body, normal gut microbiota
competes with pathogens for space and energy resources,
processes the molecules necessary to maintain mucosal integrity,
and modulate the immunological activity of the deep barrier.
In CKD and ESRD these functions are greatly compromised,
based on animal and adult patient studies. Children with similar
renal conditions are usually on a very specific diet, which
might include food low in potassium, phosphorus, and salt.
They may use phosphate binders and have restrictions on
their water consumption. During infancy and early childhood,
these restrictions could contribute to the development of an
abnormal microbial population and weaken the first line of the
gut barrier (Vaziri et al., 2013). This eventually leads to a “leaky
gut syndrome.” It also further compromises vitamin absorption
necessary for growing bodies, including Vitamin D.
We also presume that many drugs or compounds used in
the treatment of CKD and ESRD not only compromise gut
microbiome, but may experience abnormal pharmacokinetics in
the setting of abnormal intestinal permeability. In addition, the
development of new pharmacological approaches to modulate
the gut barrier components might contribute to prevention
and treatment of extra-intestinal diseases, including kidney
pathology.
Does early-life dysbiosis precede and play a role in disease
pathogenesis, or simply originate because of the disease process
itself? This question has been answered in a few diseases,
including inflammatory bowel disease, obesity, and asthma
(Arrieta et al., 2014). A paucity of data exists regarding how the
gut-renal axis functions in a growing human with renal disease
and what the role of the microbiome is in this process. Although,
some data gathered from bench research and knowledge obtained
FIGURE 1 | Continued
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FIGURE 1 | Continued
The pattern of GIT microbiome development during a child
development. Pie charts are showing profusion of the bacterial taxa at
different development stage. The gut-microbiome of the new born is primarily
colonized by Enterobacteria (Gosalbes et al., 2013). During the first month,
Bifidobacterial species pre-dominate in the gut (Koenig et al., 2011), but at
around 4–6 months is convoyed by an increase of clostridial species. Later,
the microbiome composition consists of mainly Bacteroidaceae,
Lachnospiraceae, and Ruminococcaceae, which then remains stable into
adulthood (Fanaro et al., 2005; Morelli, 2008; Lozupone et al., 2012).
from adult populations might be extrapolated to the pediatric
population, the unique growing and constantly changing body
deserves separate investigation.
One of the challenges in the study of the microbiome in
any disease, including kidney disease, in early childhood is
the greater variation in strain diversity documented during
the first few months and years of life (Viggiano et al., 2015).
Gut microbiota evolve and change during that growth. Data
showed that individuals harbor their own specific Bifidobacterial
microbiota even at the strain level. Thus, 96% of infants possessed
their own individual specific Bifidobacterial microbiota (Barrett
et al., 2015).
Study of gut microbiome in children with renal disease should
focus on four types of dysbiosis: loss of keystone taxa, loss of
diversity, shifts in metabolic capacity, and blooms of pathogens.
Both genetic and environmental factors should be taken into
consideration while studying the development of gut microbiota
composition (Spor et al., 2011). For example, one of the relevant
papers from China found that gut microbiota was involved in
melamine-induced renal injury in infants and children exposed
to melamine-tainted milk. Melamine-induced renal toxicity was
found to be mediated by the gut microbiota (Zheng et al., 2013).
Preterm children need special consideration relevant to renal
pathology. It is known that children born preterm have a
high risk of the fast progression of CKD and low nephron
numbers (Kandasamy et al., 2012; Brennan and Kandasamy,
2013; Carmody and Charlton, 2013; Mishra et al., 2014).
Many infants begin life with a significant number of immature
nephrons. They are exposed to a variety of external stressors
such as hemodynamic alterations, nephrotoxic medications,
infections, and suboptimal nutrition that can delay ongoing
FIGURE 2 | Potential mechanisms by which gut microbiome affects kidney functions.
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kidney development or cause nephron loss. Preterm infants
and particularly very low birth weight infants are also at a
disadvantage when it comes to the development of a healthy
microbiome (Gritz and Bhandari, 2015). The causes of their gut
immaturity include preterm rupture of membranes, maternal
infection, Cesarean delivery, perinatal and postnatal broad-
spectrum antibiotic exposure, exposure to other gut-modifying
medications (which might alter gut permeability), periods of
fasting, intensive care infection control standards and exposure
to resistant microbes and decreased acquaintance of human
milk (Scholtens et al., 2012; Berrington et al., 2013; Gupta
et al., 2013). Arboleya et al. (2012) compared full-term breastfed
vaginally delivered infants with preterm infants with regard
to differences in representation of 18 microbial groups within
gut flora. They demonstrated that when compared with full-
term infants, preterm infants showed increased populations
of facultative anaerobes such as Enterococcus, Enterobacter,
and Lactobacillus, increased numbers of Staphylococcus, and
decreased numbers of anaerobes such as Bifidobacterium,
Bacteroides, and Atopobium (Madan et al., 2012; Berrington et al.,
2014).
The gut microbiome specifics in relationship to kidney
compromised status were not well investigated.
Cross-sectional analysis of pediatric CKD data has
revealed valuable information that better defines the
prevalence of comorbid conditions and associated risk factors,
but not gut microbiome. Hypertension, left ventricular
hypertrophy, dyslipidemia, anemia, poor growth, and abnormal
neurocognitive development are known comorbidities that
accompany CKD (Wong et al., 2012), but pediatric gut
microbiome in a uremic milieu is yet to be evaluated.
CONCLUSION
Extensive microbiome research has been made possible by recent
advances in gene sequencing and bioinformatics tools. Further
study is required to decipher structures and functions of microbe
population in the gut of pediatric AKI, CKD, and ESRD patients.
This is a call for concerted efforts of pediatricians, pediatric
nephrologists, immunologists, microbiologists, food and
nutrition experts, and computational biologists to understand
this clinical phenomenon and further applications in developing
therapeutic regimens.
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